[Part I - Financial Information](index=4&type=section&id=Part%20I%20-%20Financial%20Information) [Financial Statements](index=4&type=section&id=Item%201%20-%20Financial%20Statements) The company reported a reduced net loss in Q1 2024, with assets decreasing but shareholders' equity increasing due to financing and a legal settlement [Interim Consolidated Balance Sheets](index=4&type=section&id=Interim%20Consolidated%20Balance%20Sheets) Total assets decreased to $7.37 million while liabilities significantly reduced, leading to an increase in shareholders' equity to $6.17 million Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2024 (Unaudited) | December 31, 2023 (Audited) | | :--- | :--- | :--- | | Cash and cash equivalents | $1,162 | $2,468 | | Total Assets | $7,367 | $8,327 | | Total Liabilities | $1,200 | $3,826 | | Total Shareholders' Equity | $6,167 | $4,501 | - The number of common shares issued and outstanding increased to **14,398,964** as of March 31, 2024, from **11,707,317** as of December 31, 2023[10](index=10&type=chunk) [Interim Consolidated Statements of Comprehensive Loss](index=5&type=section&id=Interim%20Consolidated%20Statements%20of%20Comprehensive%20Loss) The company reported a net loss of $2.37 million for Q1 2024, an improvement from $2.85 million in Q1 2023, driven by reduced expenses Statement of Comprehensive Loss (in thousands, except per share data) | Metric | Q1 2024 (Unaudited) | Q1 2023 (Unaudited) | | :--- | :--- | :--- | | Research and development, net | $(1,169) | $(1,617) | | General and administrative | $(1,215) | $(1,302) | | Operating loss | $(2,384) | $(2,919) | | Net loss | $(2,371) | $(2,853) | | Basic and diluted net loss per share | $(0.17) | $(0.36) | [Interim Consolidated Statements of Shareholders' Equity](index=6&type=section&id=Interim%20Consolidated%20Statements%20of%20Shareholders%27%20Equity) Shareholders' equity increased to $6.17 million due to common stock issuance for financing and a legal settlement, partially offset by net loss - Issued **1,685,682** shares of common stock and warrants, raising **$2.397 million**, net of issuance costs[16](index=16&type=chunk) - Issued **1,005,965** shares of common stock valued at **$1.111 million** as part of a settlement agreement[16](index=16&type=chunk)[17](index=17&type=chunk) - Share-based compensation for the quarter amounted to **$529,000**[16](index=16&type=chunk) [Interim Consolidated Statements of Cash Flows](index=7&type=section&id=Interim%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations decreased to $2.42 million, while financing activities provided $2.40 million, resulting in a $1.31 million decrease in cash Cash Flow Summary (in thousands) | Activity | Q1 2024 (Unaudited) | Q1 2023 (Unaudited) | | :--- | :--- | :--- | | Net cash used in operating activities | $(2,420) | $(3,203) | | Net cash provided by (used in) investing activities | $(1,284) | $2,883 | | Net cash provided by financing activities | $2,397 | $- | | **Decrease in cash, cash equivalents and restricted cash** | **$(1,307)** | **$(320)** | - A significant non-cash financing activity was the settlement of a legal liability through the issuance of common stock valued at **$1.111 million**[20](index=20&type=chunk) [Notes to Interim Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Interim%20Consolidated%20Financial%20Statements) Notes detail the company's pre-clinical medical device business, 'going concern' risks, royalty obligations, and a significant legal settlement - The company is a pre-clinical medical device company focused on robotic endoluminal surgery devices[22](index=22&type=chunk) - The financial statements were prepared under the assumption of the company continuing as a 'going concern', but recurring losses and the need for future funding raise substantial doubt about this ability[26](index=26&type=chunk)[27](index=27&type=chunk) - On January 26, 2024, the company settled a lawsuit from a 2017 financing, paying **$1.1 million** in cash (covered by insurance) and issuing **1,005,965** shares of restricted common stock[63](index=63&type=chunk)[64](index=64&type=chunk) - The company has royalty obligations of **3.0%-5.0%** on future sales related to grants received from the Israeli Innovation Authority (IIA)[50](index=50&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=17&type=section&id=Item%202%20-%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the LIBERTY® Endovascular Robotic Surgical System's FDA submission, decreased Q1 2024 expenses, and ongoing 'going concern' risks due to limited liquidity - The company is developing the LIBERTY® Endovascular Robotic Surgical System, described as the world's first fully disposable robotic system for endovascular procedures[85](index=85&type=chunk)[86](index=86&type=chunk) - An Investigational Device Exemption (IDE) application was submitted to the U.S. FDA on January 29, 2024, to begin human clinical trials[93](index=93&type=chunk) - The company anticipates receiving **510(k) clearance** from the FDA in the first half of 2025 and CE Mark approval in the second half of 2025[95](index=95&type=chunk) - Management believes current funds are sufficient for operations for less than one year, which raises substantial doubt about the company's ability to continue as a going concern[121](index=121&type=chunk) [Results of Operations](index=21&type=section&id=Results%20of%20Operations) Net research and development expenses decreased by $0.45 million and general and administrative expenses by $0.09 million in Q1 2024 compared to Q1 2023 Comparison of Operating Results (in thousands) | Expense Category | Q1 2024 | Q1 2023 | Change | | :--- | :--- | :--- | :--- | | Research and development expenses, net | $(1,169) | $(1,617) | $448 | | General and administrative expenses | $(1,215) | $(1,302) | $87 | - The decrease in R&D expenses was mainly due to a reduction in payroll from increased vacation utilization, government grant deductions, and lower expenses for outsourcing the manufacturing of the LIBERTY product[111](index=111&type=chunk) - The decrease in G&A expenses was primarily due to lower travel and payroll expenses, offset by increases in stock-based compensation and professional services[112](index=112&type=chunk) [Liquidity and Capital Resources](index=21&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity relies on stock issuances and grants, with $5.8 million net working capital, but current funds are sufficient for less than one year - As of March 31, 2024, the company had a net working capital of approximately **$5.8 million**[114](index=114&type=chunk) - The company raised approximately **$2.7 million** in gross proceeds from financing activities in January 2024[120](index=120&type=chunk) - The company has received a total of approximately **$1.9 million** in grants from the Israeli Innovation Authority (IIA) through March 31, 2024[116](index=116&type=chunk) - Management concludes that current cash is sufficient for less than one year, raising substantial doubt about the company's ability to continue as a going concern[121](index=121&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=23&type=section&id=Item%203%20-%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company faces market risks primarily from foreign exchange fluctuations on operating expenses, with interest rate risk deemed low and inflation impact insignificant - Primary market exposure is to interest rate sensitivity on cash and cash equivalents, but the impact of rate changes is not expected to be material due to the short-term nature of these instruments[124](index=124&type=chunk) - The company is exposed to foreign exchange risk because a substantial portion of its operating expenses are payable in currencies other than the U.S. dollar[125](index=125&type=chunk) - The company does not believe inflation had a significant impact on its results of operations[127](index=127&type=chunk) [Controls and Procedures](index=24&type=section&id=Item%204%20-%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2024, with no material changes to internal control over financial reporting - Management concluded that as of March 31, 2024, the company's disclosure controls and procedures were effective[128](index=128&type=chunk) - No changes in internal control over financial reporting occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, internal controls[129](index=129&type=chunk) [Part II - Other Information](index=24&type=section&id=Part%20II%20-%20Other%20Information) [Legal Proceedings](index=24&type=section&id=Item%201%20-%20Legal%20Proceedings) A significant lawsuit related to 2017 financing was settled in January 2024 for $1.1 million cash and over 1 million shares, leading to its discontinuation - On January 26, 2024, the company entered into a settlement agreement to resolve a lawsuit related to its 2017 equity financing[132](index=132&type=chunk) - The settlement consisted of a **$1.1 million** cash payment (covered by the company's insurance carrier) and the issuance of **1,005,965** shares of restricted common stock[133](index=133&type=chunk) - The lawsuit was formally discontinued with prejudice in February 2024[134](index=134&type=chunk) [Risk Factors](index=25&type=section&id=Item%201A%20-%20Risk%20Factors) This section is not required for a smaller reporting company - Not required for a smaller reporting company[137](index=137&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=25&type=section&id=Item%202%20-%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) There were no unregistered sales of equity securities during the period - None[138](index=138&type=chunk) [Other Information](index=25&type=section&id=Item%205%20-%20Other%20Information) No director or officer adopted or terminated a Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during Q1 2024 - No director or officer adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement during the three months ended March 31, 2024[141](index=141&type=chunk) [Exhibits](index=26&type=section&id=Item%206%20-%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including agreements, corporate governance documents, and officer certifications

BRAINTREE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ:MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today reports that the first phase of the previously announced collaboration with Corewell Health has been completed, which demonstrated the LIBERTY® System's technical capabilities and outlines potential future applications in a range of endovascular interventions. The objective of the collaboration, which will take place in multiple phases, is ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) Delaware 94-3078125 (I.R.S. Employer Identification No.) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 288 Grove Street, Suite 388 Braintree, MA 02184 (Address of principal executive of ices) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period end ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) 288 Grove Street, Suite 388 Braintree, MA 02184 (Addre ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction of In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Exact name of registrant as specified in its charter) Delaware 94-3078125 (State or Other Juri ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction o ...

Financial Performance - The company reported a net loss of $3,513,000 for the three months ended June 30, 2022, compared to a net loss of $2,511,000 for the same period in 2021, indicating an increase in loss of approximately 40.0%[11] - For the six months ended June 30, 2022, the net loss was $6,702,000, up from $4,899,000 in the same period of 2021, reflecting an increase of approximately 36.7%[11] - The company experienced a net loss of $6,702,000 for the six months ended June 30, 2022, compared to a net loss of $4,899,000 for the same period in 2021, indicating an increase in losses of approximately 36.6%[10] - The company reported basic and diluted net loss per share of $0.94 for the six months ended June 30, 2022, compared to $0.69 for the same period in 2021, indicating a worsening loss per share of approximately 36.2%[11] - The company’s net cash flows from operating activities for the six months ended June 30, 2022, were $(6,131,000), compared to $(4,291,000) for the same period in 2021, indicating a worsening cash flow situation[15] Assets and Equity - As of June 30, 2022, total assets decreased to $10,542,000 from $16,767,000 as of December 31, 2021, representing a decline of approximately 37.0%[9] - The company's cash and cash equivalents decreased to $7,294,000 as of June 30, 2022, down from $13,493,000 as of December 31, 2021, a decline of approximately 46.0%[9] - Total stockholders' equity fell to $8,540,000 as of June 30, 2022, from $14,381,000 as of December 31, 2021, representing a decrease of approximately 40.5%[9] - The company had unrestricted cash, cash equivalents, and marketable securities of approximately $9,292,000 as of June 30, 2022[26] - As of June 30, 2022, the total cash equivalents were $4,593 million, down from $8,587 million as of December 31, 2021[36] Research and Development - Research and development expenses for the three months ended June 30, 2022, were $2,193,000, compared to $1,389,000 for the same period in 2021, marking an increase of approximately 57.8%[11] - Research and development expenses for the six months ended June 30, 2022, were $3,899,000, up from $2,508,000 in the same period of 2021, reflecting a year-over-year increase of approximately 55.2%[11] - The company expects to incur additional losses for the foreseeable future due to ongoing research and development activities[27] - The company has received approximately $1,500 in grants from the Israeli Innovation Authority for research and development since 2013[45] - The repayment of grants from the Israeli government is contingent upon successful completion of research and development programs and generating sales[48] Funding and Liabilities - The company may seek to raise additional funds through future issuances of debt and/or equity securities[27] - The company has a total lease liability balance of $573 million as of June 30, 2022[44] - The company has cash payments and expenses related to operating leases amounting to $172,000 for the six months ended June 30, 2022[44] - The total future lease payments as of June 30, 2022, are summarized as $626,000, with a total lease liability balance of $573,000[44] - The company’s total liabilities decreased to $2,002,000 as of June 30, 2022, from $2,386,000 as of December 31, 2021, a reduction of approximately 16.1%[9] Stock and Shareholder Information - The company had 7,108,133 shares of common stock issued and outstanding as of June 30, 2022, unchanged from December 31, 2021[9] - The company granted stock options to purchase 100,000 shares at an exercise price of $6.48 to its CEO during the six months ended June 30, 2022[10] - The company granted options to purchase 100,000 shares to its Chairman, President, and CEO at an exercise price of $6.48, vesting over 3 years[70] - An additional 87,500 shares were granted to employees and consultants at the same exercise price and vesting schedule[71] - The company has not sold any shares of common stock under the ATM Agreement to date[54] Legal and Strategic Agreements - The company entered into an At-the-Market Offering Agreement with an aggregate offering price of up to $10,000 million[54] - The strategic collaboration agreement with Stryker aims to integrate certain instruments with the company's LIBERTY Robotic System[56] - Development activities under the collaboration with Stryker are expected to commence during the second half of 2022[59] - The Company lost an appeal in a lawsuit related to its 2017 financing, resulting in a payment of approximately $3,700 to Sabby Healthcare for 83,333 shares[61] - The ongoing litigation with Empery Asset Master Ltd. seeks rescission of the Securities Purchase Agreement and return of the $6,750 purchase price[62] Accounting and Compliance - The company is currently evaluating the impact of recently issued accounting standards on its consolidated financial statements[42] - The Company has significant uncertainties regarding the impact of COVID-19 on its operations and clinical trials[30]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____ to _____ Commission file number: 000-19871 MICROBOT MEDICAL INC. (Name of Registrant in Its Charter) Delaware 94-3078125 State or Other Jurisdiction of In ...